ArticleOmega2022
A data-driven robust optimization model by cutting hyperplanes on vaccine access uncertainty in COVID-19 vaccine supply chain.
Article in Omega, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- An integrated blockchain-enabled multi-channel vaccine supply chain network under hybrid uncertainties.Scientific reports · 2024Article
- Optimization Modeling for Pandemic Vaccine Supply Chain Management: A Review and Future Research Opportunities.Naval research logistics · 2024Article
- Optimizing the COVID-19 cold chain vaccine distribution network with medical waste management: A robust optimization approach.Expert systems with applications · 2023Article
- Fair-split distribution of multi-dose vaccines with prioritized age groups and dynamic demand: The case study of COVID-19.European journal of operational research · 2023Article
- Equitable and effective vaccine access considering vaccine hesitancy and capacity constraints.Omega · 2023Article
- Robust optimization and strategic analysis for agri-food supply chain under pandemic crisis: Case study from an emerging economy.Expert systems with applications · 2023Article
- A robust optimization problem for drone-based equitable pandemic vaccine distribution with uncertain supply.Omega · 2023Article
- Robust design of a logistics system using FePIA procedure and analysis of trade-offs between COHeliyon · 2023Article
- A data-driven optimization model to response to COVID-19 pandemic: a case study.Annals of operations research · 2023Article
- Article
- Designing a sustainable reverse supply chain network for COVID-19 vaccine waste under uncertainty.Computers & industrial engineering · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The worldwide COVID-19 pandemic sparked such a wave of concern that made access to vaccines more necessary than before. As the vaccine inaccessibility in developing countries has made pandemic eradication more difficult, this study has presented a mathematical model of a sustainable SC for the COVID-19 vaccine that covers the economic, environmental and social aspects and provides vaccine both domestically and internationally. It has also proposed a robust data-driven model based on a polyhedral uncertainty set to address the unjust worldwide vaccine distribution as an uncertain parameter. It is acceptably robust and is also less conservative than its classical counterparts. For validation, the model has been implemented in a real case in Iran, and the results have shown that it is 21% less conservative than its classical rivals (Box and Polyhedral convex uncertainty sets) in facing the uncertain parameter. As a result, the model proposes the construction of two domestic vaccine production centers, including Pasteur Institute and Razi Institute, and five foreign distributors in Tehran, Isfahan, Ahvaz, Kermanshah, and Bandar Abbas strategically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.